Extended-Interval Prophylaxis with Recombinant Factor IX FC Fusion Protein (rFIXFc) in Adults/Adolescents with Haemophilia B: Interim Results of the B-YOND Extension Study

被引：0
|
作者：
Mahlangu, J. [1 ,2 ]
Shapiro, A. D. [3 ]
Pasi, K. J. [4 ]
Ragni, M. V. [5 ]
Ozelo, M. C. [6 ]
Oldenburg, J. [7 ]
Matsushita, T. [8 ]
Baker, R. I. [9 ]
Yuan, H. [10 ]
Ramirez-Santiago, A. [10 ]
Pierce, G. F. [10 ]
Allen, G. [10 ]
Mei, B. [10 ]
机构：
[1] Univ Witwatersrand, Fac Hlth Sci, Haemophilia Comprehens Care Ctr, Johannesburg, South Africa
[2] NHLS, Johannesburg, South Africa
[3] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA
[4] Barts & London Queen Marys Sch Med & Dent, Royal London Haemophilia Ctr, London, England
[5] Univ Pittsburgh, Hemophilia Ctr Western Penn, Pittsburgh, PA USA
[6] Univ Estadual Campinas, INCT Sangue Hemoctr UNICAMP, Campinas, SP, Brazil
[7] Univ Bonn, Inst Expt Haematol & Transfus Med, Bonn, Germany
[8] Nagoya Univ Hosp, Dept Transfus Med, Nagoya, Aichi, Japan
[9] Murdoch Univ, Western Australia Ctr Thrombosis & Haemostasis, Perth, WA, Australia
[10] Biogen, Cambridge, MA USA
来源：
HAEMOPHILIA | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P044
引用
收藏
页码：46 / 47
页数：2
相关论文
共 50 条
  • [41] Assessment of recombinant factor IX-FC fusion protein (RFIXFC) clotting activity in plasma samples at canadian haemophilia treatment centres
    Geske, Jon F.
    Sadeghi-Khomami, A.
    Chaudhry, H. R.
    Sholzberg, M.
    Teitel, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 316 - 316
  • [42] Improvement in target joint bleeding during long-term use of recombinant factor IX Fc fusion protein prophylaxis in subjects with haemophilia B
    Pasi, J.
    Kulkarni, R.
    Chambost, H.
    Willemze, A.
    Feng, J.
    Jain, N.
    HAEMOPHILIA, 2019, 25 : 119 - 119
  • [43] Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years
    Shapiro, Amy
    Chaudhury, Ateefa
    Wang, Michael
    Escobar, Miguel
    Tsao, Elisa
    Barnowski, Christopher
    Feng, Jing
    Jain, Nisha
    Quon, Doris V.
    HAEMOPHILIA, 2020, 26 (06) : 975 - 983
  • [44] Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors
    Pochopien, Michal
    Tytula, Anna
    Toumi, Mondher
    Falk, Aletta
    Martone, Nicoletta
    Hakimi, Zalmai
    Eriksson, Daniel
    ADVANCES IN THERAPY, 2024, 41 (06) : 2307 - 2323
  • [45] Long-lasting recombinant factor FIX Fc fusion (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study
    Powell, J.
    Apte, S.
    Chambost, H.
    Hermans, C.
    Jackson, S.
    Josephson, N.
    Mahlangu, J.
    Ozelo, C. M.
    Peerlinck, K.
    Allen, G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 358 - 358
  • [46] Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients
    Shapiro, Amy D.
    Ragni, Margaret V.
    Valentino, Leonard A.
    Key, Nigel S.
    Josephson, Neil C.
    Powel, Jerry S.
    Cheng, Gregory
    Thompson, Arthur R.
    Goyal, Jaya
    Tubridy, Karen L.
    Peters, Robert T.
    Dumont, Jennifer A.
    Euwart, Donald
    Li, Lian
    Hallen, Bengt
    Gozzi, Peter
    Bitonti, Alan J.
    Jiang, Haiyan
    Luk, Alvin
    Pierce, Glenn F.
    BLOOD, 2012, 119 (03) : 666 - 672
  • [47] Clinical evaluation of a novel, long-lasting recombinant Fc fusion replacement factor (rFIXFc) in patients with severe haemophilia B
    Shapiro, A.
    Pasi, J.
    Gust, S.
    Defeofraulini, T.
    Thomas, G.
    Li, L.
    Dabora, S.
    Krassova, S.
    Luk, A.
    Pierce, G.
    HAEMOPHILIA, 2012, 18 : 40 - 40
  • [48] Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B
    Shapiro, Amy D.
    Pasi, K. John
    Ozelo, Margareth C.
    Kulkarni, Roshni
    Barnowski, Christopher
    Winding, Bent
    Szamosi, Johan
    Lethagen, Stefan
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2019, 3 (01) : 109 - 113
  • [49] Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study
    Nolan, Beatrice
    Mahlangu, Johnny
    Pabinger, Ingrid
    Young, Guy
    Konkle, Barbara A.
    Barnes, Chris
    Nogami, Keiji
    Santagostino, Elena
    Pasi, K. John
    Khoo, Liane
    Winding, Bent
    Yuan, Huixing
    Fruebis, Joachim
    Rudin, Dan
    Oldenburg, Johannes
    HAEMOPHILIA, 2020, 26 (03) : 494 - 502
  • [50] THIRD INTERIM ANALYSIS FROM B-MORE: A 24-MONTH PROSPECTIVE, MULTICENTRE, NON INTERVENTIONAL STUDY ON THE REAL-WORD EFFECTIVENESS AND USAGE OF RECOMBINANT FACTOR IX FC (RFIXFC) IN HAEMOPHILIA B
    Glosli, H.
    Benitez Hidalgo, O.
    Nolan, B.
    Olsson, A.
    Scott, M.
    Ahlin, H.
    Bednar, E.
    Santagostino, E.
    HAEMOPHILIA, 2023, 29 : 21 - 22
12345